|

Nivolumab-IRDye800 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Early 1: 1

Top Sponsors

  • Eben Rosenthal1

Indications

  • High Grade Glioma (HGG) of the Brain With BRAF Aberration1
  • High Grade Gliomas1
  • High Grade Glioma (III or IV)1
  • HGG1
  • Brain Cancer1

Nashville, Tennessee1 trial

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Vanderbilt University Medical Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.